Danaher Co. (NYSE:DHR) Shares Purchased by Segment Wealth Management LLC

Segment Wealth Management LLC boosted its position in Danaher Co. (NYSE:DHR) by 1.5% in the 4th quarter, Holdings Channel reports. The firm owned 61,902 shares of the conglomerate’s stock after acquiring an additional 936 shares during the quarter. Segment Wealth Management LLC’s holdings in Danaher were worth $14,210,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Decker Retirement Planning Inc. purchased a new position in Danaher in the 4th quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher in the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher during the third quarter worth approximately $40,000. FSA Wealth Management LLC purchased a new stake in Danaher in the 3rd quarter valued at $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Danaher in the 3rd quarter worth $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $238.41 on Tuesday. The firm has a market capitalization of $172.20 billion, a PE ratio of 45.50, a price-to-earnings-growth ratio of 4.30 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The business’s fifty day moving average price is $234.85 and its 200 day moving average price is $253.51. Danaher Co. has a 12 month low of $222.53 and a 12 month high of $281.70.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the company earned $2.02 EPS. On average, sell-side analysts anticipate that Danaher Co. will post 7.49 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s dividend payout ratio is presently 20.61%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. KeyCorp boosted their price target on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Stephens reissued an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. UBS Group cut their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Citigroup lowered their price objective on Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Finally, Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a research report on Thursday, October 31st. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.